64Cu MeCOSar Octreotate - Clarity Pharmaceuticals

Drug Profile

64Cu MeCOSar Octreotate - Clarity Pharmaceuticals

Alternative Names: 64-Cu-SARTATE; copper-64 labelled MeCOSar-Tyr3-octreotate

Latest Information Update: 12 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Clarity Pharmaceuticals
  • Class Diagnostic agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuroendocrine tumours
  • Phase I/II Neuroblastoma

Most Recent Events

  • 12 Mar 2018 CTP Push 700288909 - added a FE
  • 12 Mar 2018 Clarity Pharmaceuticals plans a phase I/II trial for Meningioma in Australia (ACTRN12618000309280)
  • 26 Sep 2017 Clarity Pharmaceuticals completes the phase IIa trial in Neuroendocrine tumours (Diagnosis) in Australia before September 2017 (Clarity Pharmaceuticals pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top